Helsinn Birex Pharmaceuticals, Helsinn‘s drug product manufacturing facility in Dublin, Ireland, recently obtained authorization for Manufacture of Investigational Medicinal Products (IMP) for products for human use from the Irish Medicines Board according to EU Directive 2001/20/EC. The IMP licence enables Helsinn Birex Pharmaceuticals to package, test, store and release of material for use in clinical trials. “Having this authorization expands the range of development activities...